Next Article in Journal
The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma
Next Article in Special Issue
The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
Previous Article in Journal / Special Issue
Organotypic 3D Models of the Ovarian Cancer Tumor Microenvironment
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Cancers 2018, 10(8), 266; https://doi.org/10.3390/cancers10080266

Targeting the Microenvironment in High Grade Serous Ovarian Cancer

1
Department of Obstetrics and Gynecology, Northwestern University, Chicago, IL 60611, USA
2
Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
*
Author to whom correspondence should be addressed.
Received: 20 July 2018 / Revised: 3 August 2018 / Accepted: 6 August 2018 / Published: 10 August 2018
(This article belongs to the Special Issue The Tumor Microenvironment of High Grade Serous Ovarian Cancer)
Full-Text   |   PDF [2399 KB, uploaded 10 August 2018]   |  

Abstract

Cancer–stroma interactions play a key role in cancer progression and response to standard chemotherapy. Here, we provide a summary of the mechanisms by which the major cellular components of the ovarian cancer (OC) tumor microenvironment (TME) including cancer-associated fibroblasts (CAFs), myeloid, immune, endothelial, and mesothelial cells potentiate cancer progression. High-grade serous ovarian cancer (HGSOC) is characterized by a pro-inflammatory and angiogenic signature. This profile is correlated with clinical outcomes and can be a target for therapy. Accumulation of malignant ascites in the peritoneal cavity allows for secreted factors to fuel paracrine and autocrine circuits that augment cancer cell proliferation and invasiveness. Adhesion of cancer cells to the mesothelial matrix promotes peritoneal tumor dissemination and represents another attractive target to prevent metastasis. The immunosuppressed tumor milieu of HGSOC is permissive for tumor growth and can be modulated therapeutically. Results of emerging preclinical and clinical trials testing TME-modulating therapeutics for the treatment of OC are highlighted. View Full-Text
Keywords: high-grade serous ovarian cancer; tumor microenvironment; angiogenesis; immune response; metastasis; therapeutic targeting strategies high-grade serous ovarian cancer; tumor microenvironment; angiogenesis; immune response; metastasis; therapeutic targeting strategies
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Nwani, N.G.; Sima, L.E.; Nieves-Neira, W.; Matei, D. Targeting the Microenvironment in High Grade Serous Ovarian Cancer. Cancers 2018, 10, 266.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top